Oono, Yasuhiro http://orcid.org/0000-0002-8387-0372
Kuwata, Takeshi
Takashima, Kenji
Yoda, Yusuke
Ikematsu, Hiroaki
Shitara, Kohei
Kinoshita, Takahiro
Yano, Tomonori
Article History
Received: 26 October 2017
Accepted: 23 February 2018
First Online: 2 March 2018
Compliance with ethical standards
:
: Kohei Shitara reports personal fees from Astellas Pharma, grants and personal fees from Lilly, personal fees from Bristol-Myers Squibb, personal fees from Takeda, personal fees from Pfizer, grants and personal fees from Ono Pharmaceutical, personal fees from Novartis, personal fees from Abbvie, personal fees from Yakult, grants from Dainippon Sumitomo Pharma, grants from MSD, grants from Daiichi Sankyo, grants from Taiho Pharmaceutical, grants from Chugai Pharma, outside the submitted work. Takahiro Kinoshita reports personal fees from Olympus, personal fees from Johnson & Johnson, personal fees from Medtronic, personal fees from Yakult Pharma, personal fees from Taiho Pharma, personal fees from Eli Lilly, outside the submitted work. Yasuhiro Oono, Takeshi Kuwata, Kenji Takashima, Yusuke Yoda, Hiroaki Ikematsu, and Tomonori Yano have no conflict of interests or financial ties to disclose.
: The study protocol was approved by the medical ethics committee of the National Cancer Center Hospital East (2017-053). Patient informed consent was waived due to the retrospective design of the study. This study was performed in accordance with the ethical principles outlined in the Declaration of Helsinki.